At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 70 enrolled
Drug / intervention
Botulinum toxin A +1 moredrug
Likely dose
Botulinum toxin A 100 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Botulinum Toxin Urethral Sphincter Injection for Dysfunctional Voiding - A Multicenter Study, Randomized, Double-Blind, Placebo Control
In Brief
A Phase 2 clinical trial evaluating Botulinum toxin A and Normal saline instillation for Dysfunctional Voiding. Completed, enrolled 70 participants across 1 site.
Detailed Summary
This study is designed and aimed at determine the clinical efficacy of BoNT-A on patients with dysfunctional voiding. The results of this study can provide further information for patient selection and therapeutic duration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDysfunctional Voiding
CountriesTaiwan
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2012
First PostedNov 2012
Primary CompletionFeb 2017
TodayJul 2026
First PostedNov 27, 2012
Enrollment StartOct 1, 2012
Primary CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 13.6 years ago
Interventions
Botulinum toxin Adrug
A total of 100 units of BoNT-A will be injected deeply into the external sphincter at the 3, 6, 9 and 12 o'clock positions in approximate equal aliquot.
Normal saline instillationdrug
Normal saline instillation